Conditions: Relapsing Remitting Multiple Sclerosis
Keywords: Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Fingolimod Early multiple sclerosis Naive patients
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 347
Healthy volunteers: no

Brief summary:
This study assessed the efficacy of fingolimod in patients with short duration relapsing-remitting multiple sclerosis who had not been previously treated with disease-modifying therapies (DMTs), versus patients with the same disease duration who had previously received first-line DMTs.

Detailed description:

Arms:
arm 1: Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months. arm 2: Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.

Interventions: intervention 1: Fingolimod (FTY720)
Intervention descriptions: intervention 1: Hard gelatin capsules containing 0.5 mg of fingolimod.

Protocol document: